COZAAR 100MG TABLET

País: Malasia

Idioma: inglés

Fuente: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Cómpralo ahora

Ficha técnica Ficha técnica (SPC)
19-06-2018

Ingredientes activos:

LOSARTAN POTASSIUM

Disponible desde:

MERCK SHARP & DOHME (MALAYSIA) SDN BHD

Designación común internacional (DCI):

LOSARTAN POTASSIUM

Unidades en paquete:

30Tablet Tablets; 10 Tablet Tablets

Fabricado por:

MERCK SHARP & DOHME LTD

Ficha técnica

                                LOCAL PRODUCT CIRCULAR	LPC	-MK0954	-T-032018	-Malaysia
Tablets
COZAAR	
(losartan potassium)
I. THERAPEUTIC CLASS
COZAAR (losartan potassium), the first of a new class of agents for the treatment of
hypertension, is an angiotensin II receptor (type AT 1) antagonist. COZAAR also provides a
reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in
hypertensive patients with left ventricular hypertrophy and provides renal protection for type 2
diabetic patients with proteinuria.
II. CLINICAL PHARMACOLOGY
Mechanism of Action
Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin- angiotensin
system, and a major determinant of the pa thophysiology of hypertension. Angiotensin II binds to
the AT 1
receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland, kidneys,
and the heart) and elicits several important biological actions, including vasoconstriction and the
release of aldosterone. Angiotensin II also stimulates sm ooth muscle cell proliferation. A second
angiotensin II receptor has been identified as the AT 2
receptor subtype, but it plays no known
role in cardiovascular homeostasis.
Losartan is a potent, syn thetic, orally active compound. Based on binding and pharmacological
bioassays, it binds selectively to the AT 1
receptor.
In vitro and	in vivo	, both losartan and its
pharmacologically active carboxylic acid metabolite (E -3174) block all physiologically relevant
actions of angiotensin II, regardless of the source or route of synthesis. In contrast to some
peptide antagonists of angiotensin II, losartan has no agonist effects.
1
                                
                                Leer el documento completo
                                
                            

Documentos en otros idiomas

Información para el usuario Información para el usuario malayo 18-09-2018

Buscar alertas relacionadas con este producto